NR3C2 and Hyperkalemia: Although mineralocorticoid receptor antagonists represent another pillar of treatment for patients with HFrEF, their use is lower when compared to renin-angiotensin system inhibitors or beta blockers, likely due to safety concerns, mainly hyperkalemia [1,13,15].